Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776446 | 1.00 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3L3MBTL1ALDH1A1 | |
| SCHEMBL15092018 | 0.87 | NPC1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1NPC1 | |
| SCHEMBL15092017 | 0.87 | NPC1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1NPC1 | |
| SCHEMBL18596567 | 0.87 | NPC1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1NPC1 | |
| SCHEMBL2776602 | 0.84 | FFAR1 (0.55) | SLC6A2SLC6A4SLC6A3L3MBTL1KMT2A | |
| SCHEMBL2776604 | 0.84 | FFAR1 (0.55) | SLC6A2SLC6A4SLC6A3L3MBTL1KMT2A | |
| SCHEMBL12976835 | 0.84 | L3MBTL1 (0.50) | SLC6A2SLC6A4SLC6A3L3MBTL1ALDH1A1 | |
| SCHEMBL2359242 | 0.84 | MAPT (0.56) | SLC6A2SLC6A4SLC6A3L3MBTL1ALDH1A1 | |
| SCHEMBL2359239 | 0.84 | MAPT (0.56) | SLC6A2SLC6A4SLC6A3L3MBTL1ALDH1A1 | |
| SCHEMBL15091446 | 0.83 | NPC1 (0.41) | SLC6A2SLC6A4SLC6A3NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | SLC6A2 357/4885SLC6A4 194/4885SLC6A3 441/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | SLC6A2 42/4885SLC6A4 50/4885SLC6A3 12/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | SLC6A2 42/4885SLC6A4 50/4885SLC6A3 12/4885 |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | MAOA, MAOB, PNMT | SLC6A2 353/4885SLC6A4 439/4885SLC6A3 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.